Gilead Sciences stock holds near $146 after a revenue beat

Published on 09/01/2026 at 18:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gilead Sciences stock stays firm after August 3, 2026 results showed revenue of $7.80 billion and EPS of -$6.75, both reported against consensus.

Pop-Art-Comic Gilead Sciences Forscher hält leuchtendes Reagenzglas im Biopharma-Labor — Gilead Sciences Pop-Art-Comic ISIN US3755581036 Wissenschaftler hält leuchtendes Reagenzglas Halbton Laborentdeckung bunt, Illustration mit AI erstellt.

Gilead Sciences stock (US3755581036) opened at $146.34 and the company carried a market capitalization of $181.49 billion as of August 31, 2026. The stock moved after results that showed revenue of $7.80 billion for the quarter ended August 3, 2026, above the $7.40 billion consensus estimate.

August 3 set the tone

According to MarketBeat, the latest quarter also showed earnings per share of -$6.75 versus the -$7.25 estimate, a beat of $0.50. Revenue rose 10.6 percent year over year, and the same report put the average 12-month price target at $158.04.

Guidance and yield matter

The dividend picture adds another dated figure: Gilead declared $0.82 per share for the next quarterly payout, equal to $3.28 annualized and a 2.2 percent yield. MarketBeat also cited a negative net margin of 10.64 percent and return on equity of -2.11 percent for the quarter, which keeps profitability the key question for investors.

Go deeper

Gilead Sciences results and investor context

Quarterly revenue, EPS, and the dividend remain the main data points after the August 3, 2026 report.

More on Gilead Sciences Investor Relations

HIV and oncology still drive sales

Gilead's core business still centers on HIV treatment, liver disease, and oncology, with the latest quarter showing $7.80 billion in revenue across that mix. The comparison is clear: revenue was 10.6 percent higher than a year earlier, while EPS improved by $0.50 versus consensus.

Stock level on August 31

Gilead Sciences stock was at $146.34 as of August 31, 2026, with a market capitalization of $181.49 billion. The share price sits below the cited average price target of $158.04, leaving the gap at $11.70.